바이오엔테크 (BNTX) 주가

바이오엔테크(BNTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $96.21 (-2.48%), 시가총액 $23.60B, 52주 최저~최고 $83.89 ~ $119.34.

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non

핵심 지표

• 현재가: $96.21 (-2.48%)
• 시가총액: $23.60B
• 52주 최저~최고: $83.89 ~ $119.34
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

바이오엔테크의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

바이오엔테크 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.381

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.08
• 순이익률: -0.45%
• 영업이익률: -5.77%

자주 묻는 질문